A Brampton man is appealing to the public for help funding an expensive gene therapy treatment that may save his young son’s life.
uncertain
that → appeal → life
“To us, Zorawar, is not just a child living with a rare genetic disorder,” father Mandeep Chandi said on the GoFundMe page set up for the two-year-old.
asserted
Chandi → live → old
Zorawar was diagnosed with a rare genetic disorder called Aromatic L-amino Acid Decarboxylase (AADC) deficiency.
asserted
Zorawar → diagnose → disorder
AADC is an inherited disorder that affects the way nerve cells transmit information to other cells.
asserted
cells → inherit → cells
Signs and symptoms usually make themselves known in the first six months of life.
asserted
themselves → make → life
Affected infants may have feeding problems, weak muscle tone and sleep disturbances.
uncertain
infants → have → problems
Other signs and symptoms can include developmental delays and intellectual disabilities.
asserted
signs → include → delays
Life expectancy for children with severe AADC is estimated at five to seven years.
asserted
expectancy → estimate → years
Individuals with milder forms of the disease can reach adulthood.
asserted
Individuals → reach → adulthood
“All we want is to give him every possible opportunity to live a healthier, happier life,” Chandi said.
asserted
Chandi → want → life
Falling on deaf ears
The family has approached individuals within the medical community and various levels of bureaucracy for funding, all to no avail.
asserted
family → fall → avail
“We have provided medical information, asked for guidance, and continued pursuing every possible avenue,” Chandi said, “Despite our efforts, we are still searching for a way forward.
asserted
we → provide → way
The way forward may be a trip to the United States for a gene therapy medicine called Kebildi.
uncertain
way → call → medicine
The treatment is not approved in Canada.
asserted
treatment → approve → Canada
In November 2024, the U.S. Food and Drug Administration approved Kebildi.
asserted
Administration → approve → Kebildi
The one-time therapy costs approximately $3.95 million US.
asserted
therapy → cost → US
With out-of-pocket expenses, such as specialized inpatient surgical care and follow-up, the total cost can exceed $5.5 million.
asserted
cost → exceed → million
The treatment is delivered by infusion into a precise region of the brain through a small hole in the skull during neurosurgery.
asserted
treatment → deliver → neurosurgery
“While treatment requires specialist assessment and results cannot be guaranteed, we are fighting for Zorawar to have the opportunity to be evaluated for this therapy and receive it if he is eligible,” Chandi said.
asserted
Chandi → require → it
“Results reported so far are based on 13 patients, ages 16 months to 10 years (average, 2.8 years), of whom 12 had severe AADC deficiency,” a report from Boston Children’s Hospital stated.
asserted
report → report → Hospital
“After 48 weeks of follow-up, three-quarters of the treated patients had achieved new gross motor milestones, including full head control, sitting with or without assistance, and walking.
asserted
quarters → treat → assistance
According to 2025 numbers from Fierce Pharmacy, Kebilidi is the second most expensive medicine in the U.S.
uncertain
Kebilidi → accord → U.S.
The most expensive is Lenmeldy, priced at $4.25 million US, which is one-time, custom-made gene therapy used to treat early-onset metachromatic leukodystrophy (MLD) in children.
asserted
which → price → children
PTC Therapeutics, the Texas-based company that developed the therapy, estimates the number at 5,000.
asserted
that → base → 5,000
As of Saturday afternoon, nearly $2 million had been raised on the GoFundMe, with more than 35 thousand donations given.
asserted
donations → raise → GoFundMe
The campaign aims to raise $5.5 million.
asserted
campaign → aim → million
“His smile means everything to us,” Chandi said.
asserted
Chandi → mean → us
“Every moment we spend with him is a memory we treasure.”
asserted
we → spend → him